Table 1.
First author | Publication year | Study design | Sample size | No of patients C/P | Time of outcome assessment | No of patients with first/second HVPG measurement
|
|
---|---|---|---|---|---|---|---|
C | P | ||||||
Bañares et al15 | 1999 | RCT | 28 | 14/14 | Acute | 14/14 | 14/14 |
Lin et al18 | 2004 | RCT | 22 | 11/11 | Acute | 11/11 | 11/11 |
Ren20 | 2012 | RCT | 61 | 30/31 | Acute | 30/30 | 31/31 |
Qu21 | 2012 | RCT | 54 | 25/29 | Acute | 25/25 | 29/29 |
De et al17 | 2002 | RCT | 36 | 18/18 | Acute Long-term |
18/18 18/17 |
18/18 18/16 |
Bañares et al16 | 2002 | RCT | 51 | 26/25 | Long-term | 26/24 | 25/22 |
Hobolth et al19 | 2012 | RCT | 38 | 21/17 | Long-term | 21/21 | 17/17 |
Abbreviations: No, number; C, carvedilol; P, propranolol; HVPG, hepatic vein pressure gradient; RCT, randomized controlled trial.